12:20 PM EDT, 10/29/2024 (MT Newswires) -- Coya Therapeutics ( COYA ) shares fell nearly 23% in recent Tuesday trading after the company reported results from its phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.

The placebo-controlled study evaluated two dosing regimens of subcutaneous low-dose interleukin-2, or IL-2. The trial met its primary and secondary goals for safety and enhancing regulatory T cell, or Treg, populations, respectively, the company said.

The higher total dose group, however, "did not exhibit benefits in exploratory endpoints, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on cerebrospinal fluid biomarkers and cognitive outcomes," the company said.

Exploratory endpoints of the study examined changes in cerebrospinal fluid, Alzheimer's Disease-related biomarkers, and cognitive status, the company added.

Price: 7.87, Change: -2.33, Percent Change: -22.82